Abstract:The neurobiology of major depressive disorder (MDD) remains incompletely understood, and many individuals fail to respond to standard treatments. Repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex (DLPFC) has emerged as a promising antidepressant therapy. However, the heterogeneity of response underscores a pressing need for biomarkers of treatment outcome. We acquired resting state functional magnetic resonance imaging (rsfMRI) data in 47 MDD individuals prior to 5-8 weeks of rTMS treatment targeted using the F3 beam approach and in 29 healthy comparison subjects. The caudate, prefrontal cortex, and thalamus showed significantly lower blood oxygenation level-dependent (BOLD) signal power in MDD individuals at baseline. Critically, individuals who responded best to treatment were associated with lower pre-treatment BOLD power in these regions. Additionally, functional connectivity (FC) in the default mode and affective networks was associated with treatment response. We leveraged these findings to train support vector machines (SVMs) to predict individual treatment responses, based on learned patterns of baseline FC, BOLD signal power and clinical features. Treatment response (responder vs. nonresponder) was predicted with 85-95% accuracy. Reduction in symptoms was predicted to within a mean error of ±16% (r = .68, p < .001). These preliminary findings suggest that therapeutic outcome to DLPFC-rTMS could be predicted at a clinically meaningful level using only a small number of core neurobiological features of MDD, warranting prospective testing to ascertain generalizability. This provides a novel, transparent and physiologically plausible multivariate approach for classification of individual response to what has become the most commonly employed rTMS treatment worldwide. This study utilizes data from a larger clinical study (Australian New Zealand Clinical Trials Registry: Investigating Predictors of Response to Transcranial Magnetic Stimulation for the Treatment of Depression; ACTRN12610001071011; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336262).

Peripheral Biomarkers of Cognitive Response to Dopamine Receptor Agonist Treatment

COMT, 5-HTR2A, and SLC6A4 Mrna Expressions in First-Episode Antipsychotic-Naïve Schizophrenia and Association with Treatment Outcomes

Shared and Divergent Transcriptomic Regulation in Nucleus Accumbens D1 and D2 Medium Spiny Neurons by Cocaine and Morphine

Influence of Compulsivity of Drug Abuse on Dopaminergic Modulation of Attentional Bias in Stimulant Dependence.

Dopamine Release in Dissociable Striatal Subregions Predicts the Different Effects of Oral Methylphenidate on Reversal Learning and Spatial Working Memory

Identifying methamphetamine use predictors in HIV infection: Immune-dopaminergic signatures in peripheral leukocytes and the role of COMT genotype

Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis

Response Perseveration in Stimulant Dependence is Associated with Striatal Dysfunction and Can Be Ameliorated by a D(2/3) Receptor Agonist.

Long-Term Stimulant Treatment Affects Brain Dopamine Transporter Level in Patients with Attention Deficit Hyperactive Disorder

Dopamine D2 receptor stimulation modulates the balance between ignoring and updating according to baseline working memory ability

Metabolomics changes after rTMS intervention reveal potential peripheral biomarkers in methamphetamine dependence

Exploring peripheral biomarkers in psychostimulant use: A systematic review on neurotrophins, stress-related hormones, oxidative stress molecules and genetic factors.

Neural and Cognitive Predictors of Stimulant Treatment Efficacy in Medication-Naïve ADHD Adults: A Pilot Diffusion Tensor Imaging Study

Novel pharmacokinetic model to estimate dopamine dynamics in humans using PET

The dopamine 3 receptor as a candidate biomarker and therapeutic for opioid use disorder

Hereditary and cortical morphological biomarker of sensitivity to reward in short-term withdrawal methamphetamine abusers

Neurophysiological Predictors of Response to Medication in Parkinson's Disease

Decline in striatal binding ratio associated with accelerated decline in performance on Symbol Digit Modality but not MoCA in Parkinson's disease psychosis

Cognitive Function and Nigrostriatal Markers in Abstinent Methamphetamine Abusers

A multivariate neuroimaging biomarker of individual outcome to transcranial magnetic stimulation in depression

Cognitive and Emotional Predictors of Real Versus Sham Repetitive Transcranial Magnetic Stimulation Treatment Response in Methamphetamine Use Disorder.